---
title: "UNBX.US (UNBX.US) — 相关新闻"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/UNBX.US/news.md"
symbol: "UNBX.US"
name: "UNBX.US"
parent: "https://longbridge.com/zh-CN/quote/UNBX.US.md"
datetime: "2026-03-10T13:20:36.616Z"
locales:
  - [en](https://longbridge.com/en/quote/UNBX.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/UNBX.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/UNBX.US/news.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/UNBX.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/UNBX.US/news.md)


# UNBX.US (UNBX.US) — 相关新闻

### [UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting](https://longbridge.com/zh-CN/news/238443543.md)
*2025-05-01T12:33:13.000Z*
> SOUTH SAN FRANCISCO, Calif., May 01, 2025 ( GLOBE NEWSWIRE ) -- UNITY Biotechnology, Inc. ( "UNITY" ) [NASDAQ: UBX], a b

### [Unity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock Falls](https://longbridge.com/zh-CN/news/232995851.md)
*2025-03-24T16:08:01.000Z*
> UBX1325-treated patients saw a mean BCVA gain of +5.5 ETDRS letters at 36 weeks. Unity plans to release full 36-week dat

### [Unity Biotechnology's Phase 2b Study Misses Primary Analysis Endpoint, Stock Falls In Pre-Market](https://longbridge.com/zh-CN/news/232959035.md)
*2025-03-24T11:52:17.000Z*
> Unity Biotechnology, Inc. (UBX) announced topline results from its Phase 2b ASPIRE trial for UBX1325 in diabetic macular

### [UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE Study of UBX1325 in Patients with Diabetic Macular Edema (DME) on March 24, 2025 | UBX Stock News](https://longbridge.com/zh-CN/news/232869953.md)
*2025-03-23T20:00:00.000Z*
> UNITY Biotechnology will host a virtual investor event on March 24, 2025, at 8:00 AM ET to discuss the 24- and 36-week d

### [Unity Biotechnology Reports 2024 Financial Results and Updates](https://longbridge.com/zh-CN/news/231099157.md)
*2025-03-09T03:51:12.000Z*
> Unity Biotechnology (UBX) reported its Q4 and full-year 2024 financial results, highlighting a net loss of $26 million,